Black Health
GLP-1 receptor agonist Type 2 diabetes Obesity Cardiovascular risk reduction

Semaglutide (Ozempic, Wegovy, Rybelsus) and Black patients

Brand names: Ozempic, Wegovy, Rybelsus

Last reviewed: Sources checked:

What Semaglutide does

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural gut hormone. It lowers blood glucose, slows gastric emptying, reduces appetite, and — at higher doses — produces substantial weight loss. It is given once weekly by injection (Ozempic, Wegovy) or once daily by mouth (Rybelsus).

What the evidence says for Black patients

Semaglutide's cardiovascular and glycemic benefits are consistent across racial groups in the trials that enrolled Black participants:

  • SUSTAIN-6 (Marso et al., NEJM 2016;375:1834–44, PMID 27633186) showed a 26 percent reduction in MACE in type-2 diabetes with cardiovascular risk, including a pre-specified analysis supporting consistency across race subgroups.
  • SELECT (Lincoff et al., NEJM 2023;389:2221–32, PMID 37952131) established cardiovascular risk reduction with semaglutide 2.4 mg in people with obesity but without diabetes, with consistent effects in Black participants.
  • STEP 1 (Wilding et al., NEJM 2021;384:989–1002) showed ~15 percent mean weight loss with semaglutide 2.4 mg; the Black subgroup experienced meaningful weight loss though average loss was slightly lower than in white participants, a pattern seen in most obesity trials and not unique to GLP-1s.

Equity context:

  • Black adults bear a disproportionate burden of type 2 diabetes, obesity, and cardiovascular disease — populations who would benefit most from semaglutide.
  • Yet pharmacy-claims analyses (Eberly et al., JAMA Health Forum 2021;2:e214182) show Black adults are less likely to be prescribed GLP-1s than white adults with similar clinical profiles.
  • Cost remains the dominant access barrier. The list price of Wegovy in the US is over $1,300 per month; Medicare Part D cannot cover obesity alone but can cover it for cardiovascular risk reduction (post-SELECT) when labeled for that indication.

Common alternatives

Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist with even greater weight-loss efficacy. Dulaglutide (Trulicity) and liraglutide (Victoza, Saxenda) are other GLP-1s. For type 2 diabetes without obesity, metformin plus an SGLT2 inhibitor is often a reasonable alternative.

Side effects

  • Nausea, vomiting, diarrhea — most common, usually improves after dose titration
  • Delayed gastric emptying; small-bowel obstruction has been reported rarely
  • Pancreatitis (rare)
  • Gallbladder disease
  • Injection-site reactions
  • Boxed warning for thyroid C-cell tumors (rodent signal; human relevance uncertain). Contraindicated in personal or family history of medullary thyroid cancer or MEN2.
  • Rare diabetic retinopathy progression in patients with pre-existing retinopathy

Factors that affect adherence

GI side effects cause early discontinuation in up to a quarter of patients; careful dose escalation (0.25 → 0.5 → 1.0 → 2.0 mg weekly over months) and dietary adjustment (smaller, lower-fat meals) substantially improve tolerability. Cost is the main systemic barrier; manufacturer savings programs and Medicare Part D coverage vary. Commercial pharmacy shortages in 2022–2024 have intermittently made all forms of semaglutide hard to obtain.

Questions to ask your doctor

Bring this list to your next appointment.

  • Is my insurance likely to cover Ozempic or Wegovy for my situation?
  • If cost is an issue, is Rybelsus, dulaglutide, or tirzepatide more accessible?
  • What's the dose-escalation schedule, and what do I do if I can't tolerate a dose step?
  • Should I have an eye exam before starting if I have retinopathy?

References

  1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). NEJM. 2016;375:1834–1844. PMID 27633186.
  2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM. 2023;389:2221–2232. PMID 37952131.
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384:989–1002.
  4. Eberly LA, Yang L, Eneanya ND, et al. Racial/ethnic and socioeconomic disparities in management of incident diabetes. JAMA Health Forum. 2021;2:e214182.
  5. U.S. Food and Drug Administration. Ozempic (semaglutide) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.